Top

Journal of Endocrinological Investigation

Published in:

Open Access 05-06-2024 | Molecular Imaging | Review

Endocrinology application of molecular imaging: current role of PET/CT

Authors: L. Calderoni, L. Giovanella, S. Fanti

Published in: Journal of Endocrinological Investigation | Issue 10/2024

Abstract

Background

In recent years, nuclear medicine imaging methods have proven to be of paramount importance in a wide variety of diseases, particularly in oncology, where they are crucial for assessing the extent of disease when conventional methods fall short. Moreover, nuclear imaging modalities are able to better characterize lesions using target agents related to specific pathways (e.g. glucose metabolism, cellular proliferation, amino acid transport, lipid metabolism, specific receptor ligands). The clinical presentation of endocrine diseases encompasses a broad spectrum of sign and symptoms. Moreover, endocrine tumors show varying degrees of aggressiveness from well differentiated and indolent to highly aggressive cancers, respectively.

Rationale

With the application of new medicinal radio-compounds and increasingly advanced tomographic imaging technology, the utility of Positron Emission Tomography/Computed Tomography (PET/CT) in the field of endocrine diseases is expanding.

Aim

This review aims to analyze and summarize the primary indications of PET/CT, providing a practical approach for clinicians. A comprehensive literature search on PubMed was conducted to provide an updated overview of the available evidence regarding the use of PET/CT in endocrinology. Within this review, we will discuss the applications of PET/CT, compare different radiopharmaceuticals and highlight the uptake mechanism, excluding neuroendocrine carcinomas from discussion.

Conclusions

PET/CT is a valuable tool in diagnosing and managing endocrine disorders due to its capacity to furnish both functional and anatomical information, facilitate early lesion detection, guide treatment decisions, and monitor treatment response. Its non-invasive nature and precision make it an integral component of modern endocrine healthcare. This review aims to provide physicians with a clear perspective on the role of PET/CT imaging, discussing its emerging opportunities and appropriateness of use in endocrinological diseases.

Anand SS, Singh H, Dash AK (2009) Clinical applications of PET and PET-CT. Med J Armed Forces India 65(4):353–358. https://doi.org/10.1016/S0377-1237(09)80099-3. (Epub 2011 Jul 21. PMID: 27408291; PMCID: PMC4921358)CrossRefPubMedPubMedCentral

Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L, Giordano A (2012) Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37(6):1004–1020. https://doi.org/10.1007/s00261-012-9871-9. (PMID: 22422069)CrossRefPubMed

Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, Strauss HW (2020) The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med 61(Suppl 2):263S-272S. https://doi.org/10.2967/jnumed.120.254532. (PMID: 33293447)CrossRefPubMed

Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B, Kroiss AS (2021) PET with different radiopharmaceuticals in neuroendocrine neoplasms: an umbrella review of published meta-analyses. Cancers (Basel) 13(20):5172. https://doi.org/10.3390/cancers13205172.PMID:34680321;PMCID:PMC8533943CrossRefPubMed

Schöder H, Erdi YE, Larson SM, Yeung HW (2003) PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 30(10):1419–1437. https://doi.org/10.1007/s00259-003-1299-6. (Epub 2003 Sep 5 PMID: 12961037)CrossRefPubMed

Volterrani D et al (2022) Nuclear oncology: from pathophysiology to clinical applications. Springer International Publishing (10.1007/978-3-031-05494-5)

Cao L et al (2023) (18)F-FDG-PET/CT-based machine learning model evaluates indeterminate adrenal nodules in patients with extra-adrenal malignancies. World J Surg Oncol 21(1):305PubMedPubMedCentral

Aphale R et al (2023) Impact of fluoro-choline PET/CT in reduction in failed parathyroid localization in primary hyperparathyroidism. World J Surg 47(5):1231–1237PubMed

Saha S et al (2023) C(11) choline PET/CT succeeds when conventional imaging for primary hyperparathyroidism fails. Surgery 173(1):117–123PubMed

10.

Wei F et al (2023) Comparison of 18 F-FDOPA and 18 F-MFBG PET/CT images of metastatic pheochromocytoma. Clin Nucl Med 48(7):638–639PubMed

11.

Fortunati E, Bonazzi N, Zanoni L, Fanti S, Ambrosini V (2023) Molecular imaging theranostics of neuroendocrine tumors. Semin Nucl Med 53(4):539–554. https://doi.org/10.1053/j.semnuclmed.2022.12.007. (Epub 2023 Jan 7. PMID: 36623974)CrossRefPubMed

12.

Alevroudis E, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K (2021) Clinical utility of 18F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis. Cancers (Basel) 13(8):1813. https://doi.org/10.3390/cancers13081813. (PMID: 33920195; PMCID: PMC8069875)CrossRefPubMed

13.

Jiang H et al (2017) Safety, pharmacokinetics, metabolism and radiation dosimetry of (18)F-tetrafluoroborate ((18)F-TFB) in healthy human subjects. EJNMMI Res 7(1):90PubMedPubMedCentral

14.

Jiang H, DeGrado TR (2018) [(18)F]Tetrafluoroborate ([(18)F]TFB) and its analogs for PET imaging of the sodium/iodide symporter. Theranostics 8(14):3918–3931PubMedPubMedCentral

15.

Dudczak R, Traub-Weidinger T (2010) PET and PET/CT in endocrine tumours. Eur J Radiol. https://doi.org/10.1016/j.ejrad.2009.12.024CrossRefPubMed

16.

Hargitai L, Clerici T, Musholt TJ, Riss P (2023) Surgery for primary hyperparathyroidism in Germany, Switzerland, and Austria: an analysis of data from the EUROCRINE registry. Langenbecks Arch Surg 408(1):150PubMedPubMedCentral

17.

Patel DD et al (2023) Comparison of 4D computed tomography and F-18 fluorocholine PET for localisation of parathyroid lesions in primary hyperparathyroidism: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 99(3):262–271PubMed

18.

Talbot JN et al (2023) 18F-fluorocholine PET/CT detects parathyroid gland hyperplasia as well as adenoma: 401 PET/CTs in one center. Q J Nucl Med Mol Imaging 67(2):96–113PubMed

19.

Kołodziej M et al (2022) Usefulness of PET/CT with carbon-11-labeled methionine in the diagnosis of tertiary hyperparathyroidism. Nutrients 15(1):188PubMedPubMedCentral

20.

Huynh KA et al (2023) Diagnostic utility of (11) C-methionine PET/CT in primary hyperparathyroidism in a UK cohort: a single-centre experience and literature review. Clin Endocrinol (Oxf) 99(3):233–245PubMed

21.

Bijnens J et al (2022) Retrospective real-life study on preoperative imaging for minimally invasive parathyroidectomy in primary hyperparathyroidism. Sci Rep 12(1):17427PubMedPubMedCentral

22.

Tlili G et al (2023) Dual-tracer 99mTc-sestamibi/ 123I imaging in primary hyperparathyroidism. Q J Nucl Med Mol Imaging 67(2):114–121PubMed

23.

Carral F et al (2021) Safety and diagnostic performance of parathyroid hormone assay in fine-needle aspirate in suspicious parathyroid adenomas. Endocrinol Diabetes Nutr (Engl Ed) 68(7):481–488PubMed

24.

PetranovićOvčariček P et al (2021) The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging 48(9):2801–2822

25.

Vestergaard S et al (2023) Head-to-head comparison of Tc-99m-sestamibi SPECT/CT and C-11-L-Methionin PET/CT in parathyroid scanning before operation for primary hyperparathyroidism. Mol Imaging Biol 25(4):720–726PubMed

26.

Fiz F et al (2023) [18F]F-Choline PET/CT and 4D-CT in the evaluation of primary hyperparathyroidism: rivals or allies? Q J Nucl Med Mol Imaging 67(2):130–137PubMed

27.

Kluijfhout WP et al (2016) Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg 401(7):925–935PubMedPubMedCentral

28.

Bilen N et al (2023) Analysis of intraoperative laboratory measurements and imaging techniques such as Tc-99 m-MIBI SPECT/CT, 18F-fluorocholine PET/CT and ultrasound in patients operated with prediagnosis of parathyroid adenoma. Ir J Med Sci 192(4):1695–1702PubMed

29.

Rogic I, Huic D (2023) Detection of brown tumors by [18F]F-choline PET/CT performed in a patient with secondary hyperparathyroidism. Nucl Med Rev Cent East Eur 26:49–51PubMed

30.

Werner J et al (2023) Localization of brown tumors with 18 F-Fluorocholine PET/CT Imaging in severe primary hyperparathyroidism. Clin Nucl Med 48(8):e387–e389PubMed

31.

Jacquet-Francillon N, Prevot N (2023) Brown tumors in nuclear medicine: a systematic review. Ann Nucl Med 37(5):255–270PubMed

32.

Terroir M et al (2019) Parathyroid glands hyperplasias mimicking medullary thyroid carcinoma metastatic lymph nodes on 18F-DOPA PET/CT. Clin Nucl Med 44(8):e497–e498PubMed

33.

Göbüt H, Bostanci H (2023) The evolution of primary hyperparathyroidism publications and global productivity from past to present: a bibliometric analysis during 1980 to 2022. Medicine (Baltimore) 102(35):e34622PubMed

34.

Su C et al (2022) Diagnosis and treatment of liver metastases of parathyroid carcinoma. Front Endocrinol (Lausanne) 13:982972PubMed

35.

Almasi CE et al (2023) Indeterminate thyroid cytology in an iodine-deficient population: prevalence, operation rate, risk of malignancy anddiagnostic value of thyroid scintigraphy and (18)F-FDG PET imaging parameters. Hell J Nucl Med 26(1):2–8PubMed

36.

Giovanella L et al (2019) EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging 46(12):2514–2525PubMed

37.

de Koster EJ et al (2023) [(18)F]FDG uptake and expression of immunohistochemical markers related to glycolysis, hypoxia, and proliferation in indeterminate thyroid nodules. Mol Imaging Biol 25(3):483–494PubMed

38.

de Koster EJ, de Geus-Oei LF, Brouwers AH, van Dam EWCM, Dijkhorst-Oei LT, van Engen-van Grunsven ACH, van den Hout WB, Klooker TK, Netea-Maier RT, Snel M, Oyen WJG, Vriens D, EfFECTS trial study group (2022) [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-021-05627-2CrossRefPubMedPubMedCentral

39.

Familiar C et al (2023) Prevalence and clinical significance in our setting of incidental uptake in the thyroid gland found on 18F-fluordeoxyglucose positron emission tomography-computed tomography (PET-CT). Endocrinol Diabetes Nutr (Engl Ed) 70(3):171–178PubMed

40.

de Leijer JF et al (2021) Focal thyroid incidentalomas on (18)F-FDG PET/CT: a systematic review and meta-analysis on prevalence, risk of malignancy and inconclusive fine needle aspiration. Front Endocrinol (Lausanne) 12:723394PubMed

41.

Matsuo M et al (2023) Utility of FDG PET at the initial radioiodine therapy in differentiated thyroid cancer. Anticancer Res 43(1):183–190PubMed

42.

Forrer F et al (2022) Variations in radioiodine therapy in europe: decision-making after total thyroidectomy. Oncology 100(2):74–81PubMed

43.

Giovanella L et al (2022) Molecular imaging and theragnostics of thyroid cancers. Cancers (Basel) 14(5):1272PubMed

44.

Askar HAA, Farghali RM, Mekkaway MA, Bashank NM (2023) Correlation between metabolic uptake of F-18-FDG-PET/computed tomography and thyroglobulin level in differentiated thyroid cancer patients with suspected recurrence. Nucl Med Commun 44(7):640–645PubMed

45.

Santhanam P et al (2017) Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 86(5):645–651PubMed

46.

Mu X et al (2023) [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 50(4):1205–1215PubMed

47.

Sayiner ZA et al (2023) Comparison of (68)Ga-FAPI-04 and (18)F-FDG PET/CT for diagnosis of metastatic lesions in patients with recurrent papillary thyroid carcinoma. Hell J Nucl Med 26(1):41–46PubMed

48.

PetranovićOvčariček P et al (2023) Molecular theranostics in radioiodine-refractory differentiated thyroid cancer. Cancers (Basel) 15(17):4290

49.

Zhang Y, Li Y, Lin Z, Chen W (2023) Can 99 Tc m -3PRGD 2 (α ν β 3) and 18 F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report. Medicine (Baltimore) 102(5):e32751PubMed

50.

Li P et al (2023) Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review. Nucl Med Commun. https://doi.org/10.1097/MNM.0000000000001773CrossRefPubMedPubMedCentral

51.

Treglia G, Rufini V, Piccardo A, Imperiale A (2023) Update on management of medullary thyroid carcinoma: focus on nuclear medicine. Semin Nucl Med 53(4):481–489PubMed

52.

Trimboli P, Mian C, Piccardo A, Treglia G (2023) Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine 81(2):183–193PubMedPubMedCentral

53.

Li JY, Chen J, Liu J, Zhang SZ (2023) Simultaneous rectal neuroendocrine tumors and pituitary adenoma: a case report and review of literature. World J Gastroenterol 29(34):5082–5090PubMedPubMedCentral

54.

Ballal S et al (2023) Head-to-head comparison of [(68)Ga]Ga-DOTA.SA.FAPi and [(68)Ga]Ga-DOTANOC positron emission tomography/computed tomography imaging for the follow-up surveillance of patients with medullary thyroid cancer. Thyroid 33(8):974–982PubMed

55.

Maciel J et al (2023) Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center. Hormones (Athens) 22(1):131–138PubMed

56.

Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E, Kharlip J, American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons (2009) American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract 15(5):450–453. https://doi.org/10.4158/EP.15.5.450CrossRefPubMed

57.

Mody RN et al (2021) ACR Appropriateness Criteria^® adrenal mass evaluation: 2021 update. J Am Coll Radiol 18(11s):S251-s267PubMed

58.

van Doesburg JR et al (2023) Incidence and oncological implication of adrenal incidentalomas in esophageal cancer patients. Dis Esophagus. https://doi.org/10.1093/dote/doad003CrossRefPubMedPubMedCentral

59.

Schaafsma M et al (2023) The diagnostic value of 18F-FDG PET/CT scan in characterizing adrenal tumors. J Clin Endocrinol Metab 108(9):2435–2445PubMed

60.

Werner RA et al (2022) Adrenal functional imaging. Presse Med 51(2):104114PubMed

61.

Hu J et al (2023) Accuracy of gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism. JAMA Netw Open 6(2):e2255609PubMedPubMedCentral

62.

Wu X et al (2023) [(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med 29(1):190–202PubMedPubMedCentral

63.

Kaplan İ et al (2023) Superiority of 18 F-FDG PET/CT to 68 GA-FAPI PET/CT in adrenocortical tumor imaging. Clin Nucl Med 48(6):e307–e309PubMed

64.

Taïeb D et al (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39(12):1977–1995PubMedPubMedCentral

65.

Bozkurt MF et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44(9):1588–1601PubMed

66.

Franzius C et al (2008) Procedure guidelines for MIBG-scintigraphy in children. Nuklearmedizin 47(3):132–138PubMed

67.

Marcus C, Subramaniam RM (2023) Paragangliomas and pheochromocytomas: positron emission tomography/computed tomography diagnosis and therapy. PET Clin 18(2):233–242PubMed

68.

Goujon A et al (2023) 18 F-FDOPA PET/CT of paraganglioma in the spermatic cord. Clin Nucl Med 48(5):e232–e234PubMed

69.

Pauwels E et al (2023) [(18)F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [(123)I] MIBG in neural crest tumour patients. Eur J Nucl Med Mol Imaging 50(4):1134–1145PubMed

70.

Alaklabi AM, Arabi TZ, Bin Saeedan MN, Alotaibi GS (2023) A young patient with undiagnosed polycythemia-paraganglioma syndrome: a case report. Am J Case Rep 24:938676

71.

de Jong MC, Pinto D, Parameswaran R (2023) Reduced uptake pattern on (68) Ga-DOTATATE-scan may indicate necrosis predicting aggressive behavior in pheochromocytoma and paragangliomas (PPGLs). J Surg Oncol 128(5):764–768PubMed

72.

Gillett D et al (2023) Molecular imaging of pituitary tumors. Semin Nucl Med 53(4):530–538PubMed

73.

Kim K et al (2023) Dexamethasone suppression for (18)F-FDG PET/CT to localize ACTH-secreting pituitary tumors. Cancer Imaging 23(1):85PubMedPubMedCentral

74.

Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SD, de Win MML, Bot JCJ, Aronica E, Post R, Hoogmoed J, Drent ML, Pereira AM (2023) Continuing challenges in the definitive diagnosis of Cushing’s disease: a structured review focusing on molecular imaging and a proposal for diagnostic work-up. J Clin Med 12(8):2919. https://doi.org/10.3390/jcm12082919CrossRefPubMedPubMedCentral

75.

Jia M et al (2023) Case series: primary aldosteronism diagnosed despite normal screening investigations: a report of three cases. Medicine (Baltimore) 102(20):e33724PubMed

76.

de Herder WW (2016) Molecular imaging of pituitary pathology. Front Horm Res 45:133–141PubMed

Title: Endocrinology application of molecular imaging: current role of PET/CT
Authors: L. Calderoni
L. Giovanella
S. Fanti
Publication date: 05-06-2024
Publisher: Springer International Publishing
Keywords: Molecular Imaging
Endocrinology
Diagnostics in Endocrinology
Parathyroid Disease
Hyperparathyroidism
Thyroid Disease
Thyroid Cancer
Disease of the Adrenal Glands
Adrenal Cancer
Cushing's Syndrome
Pituitary Adenoma
Published in: Journal of Endocrinological Investigation / Issue 10/2024
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02400-8

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

ERS Congress 2024

Springer Medicine

Endocrinology application of molecular imaging: current role of PET/CT

Abstract

Background

Rationale

Aim

Conclusions

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Background

Rationale

Aim

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2024

Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease

Mouse model of Graves’ orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene

Development of a diagnostic model for pre-washout screening of primary aldosteronism

Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy

The use of telecytology for the evaluation of thyroid nodules fine-needle aspiration biopsy specimens: a systematic review

Evaluation of pituitary function and metabolic parameters in patients with traumatic maxillofacial fractures

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials